Reduction in plasma norepinephrine during fenfluramine treatment.
Plasma norepinephrine levels were reduced to 30% of placebo levels during the administration of fenfluramine, 120 mg/day, for 10 or more days. There was also a significant reduction in plasma dopamine beta-hydroxylase activity during fenfluramine treatment, suggesting that chronic administration may induce antiadrenergic effects which may be useful in the treatment of disorders affected by circulating catecholamines.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy; D003864:Depression, Chemical; D004299:Dopamine beta-Hydroxylase / Q000097:blood; D005260:Female; D005277:Fenfluramine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood*; D011187:Posture; D011674:Pulse / Q000187:drug effects; D013997:Time Factors
D005277:Fenfluramine; D004299:Dopamine beta-Hydroxylase; D009638:Norepinephrine